CN111269260B - Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof - Google Patents

Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof Download PDF

Info

Publication number
CN111269260B
CN111269260B CN201911364658.XA CN201911364658A CN111269260B CN 111269260 B CN111269260 B CN 111269260B CN 201911364658 A CN201911364658 A CN 201911364658A CN 111269260 B CN111269260 B CN 111269260B
Authority
CN
China
Prior art keywords
tin
phenylpropyl
methyl
bromothiophene
tris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911364658.XA
Other languages
Chinese (zh)
Other versions
CN111269260A (en
Inventor
朱小明
冯泳兰
蒋伍玖
张复兴
庾江喜
邝代治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyang Normal University
Original Assignee
Hengyang Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyang Normal University filed Critical Hengyang Normal University
Priority to CN201911364658.XA priority Critical patent/CN111269260B/en
Publication of CN111269260A publication Critical patent/CN111269260A/en
Application granted granted Critical
Publication of CN111269260B publication Critical patent/CN111269260B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22Tin compounds
    • C07F7/2224Compounds having one or more tin-oxygen linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

The invention discloses a tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex, and a preparation method and application thereof, and the complex is shown in the following structural formula (I):

Description

Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof
Technical Field
The invention relates to a tri (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex, a preparation method thereof and application of the complex in preparing antitumor drugs.
Background
Since Brown first discovered organotin carboxylates (CH 3 CO 2 SnPh 3 ) The synthesis, structure and biological activity research of the organotin carboxylate complex are widely focused by scientists since the biological activity of inhibiting the tumor of mice is inhibited. However, the known organotin compounds are generally highly toxic and therefore limited in application. Studies have shown that the structure, reactivity and biological activity of organotin compounds are related to both the hydrocarbon-based structure directly attached to the tin atom and the nature of the ligand. The organic tin complex structure is optimized through molecular design, so that the balance between toxicity and biological activity of the organic tin complex is regulated, and the organic tin complex is an important direction of current research. The coordination mode of tin atoms can be greatly changed by functionalizing hydrocarbon groups or ligands, so that the biological activity of the organotin complex is affected. Studies have shown that the toxicity of organotin compounds is related to their relative molecular masses, with smaller relative molecular masses being more toxic and larger relative molecular masses being more bulky hydrocarbyl tin. Therefore, the novel large steric hindrance alkyl tin complex is synthesized, and the structure and the biological activity of the complex are researched, so that the complex has important research significance.
It is well known that azacyclic rings are important and common structural units of medicines, pesticides, functional materials, etc., most of which are closely related to life systems, so that studying the structure of organotin derivatives of such ligands can provide useful information not only for the disclosed anticancer mechanism, but also for the development of novel drugs as possible molecular designs. It is necessary to synthesize a novel nitrogen-containing heterocyclic organotin carboxylate compound and conduct a study on the bioactivity of the compound, the nitrogen-containing heteroatom carboxylic acid being an important carboxylic acid ligand. For example, chinese patent CN101402650B discloses an application of a dibutyl tin and quinolinecarboxylic acid complex in preparing medicines for treating gastric cancer, nasopharyngeal carcinoma, human liver cancer or leukemia.
Based on the characteristics that the bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide is a substance with better biological activity, and the 2-methyl-2-phenylpropyl has larger steric hindrance, larger molecular weight and the like, the bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide is selected to react with 3-bromothiophene-2-formic acid serving as a heterocyclic carboxylic acid ligand under certain conditions, and a complex with stronger inhibition activity on A549 (human lung cancer cells), hela (human cervical cancer cells) and HGC-27 (human gastric cancer cells) is synthesized, so that a new approach is provided for developing anticancer drugs.
Disclosure of Invention
In view of the above problems of the prior art, a first object of the present invention is to provide a tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex.
A second object of the present invention is to provide a process for preparing the above tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex.
The third object of the invention is to provide the application of the tri (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex in preparing anticancer drugs.
As a first aspect of the present invention, a tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex is a complex of the following structural formula (I):
(I)。
the three (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex is subjected to elemental analysis, infrared spectrum analysis, nuclear magnetic resonance spectrum and X-ray single crystal structure analysis, and the results are as follows:
elemental analysis (C) 35 H 41 BrO 2 SSn): theoretical value: c,58.03; h,5.71. Measurement value: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)。
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex of the present invention has a crystal structure, and the crystallographic data thereof are as follows: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex of the invention is structurally characterized in that: the central tin in the molecule forms a distorted tetrahedral configuration with the coordinating atoms.
As a preparation method of the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex, bis [ tris (2-methyl-2-phenylpropyl) ] tin, 3-bromothiophene-2-formic acid and toluene serving as solvents are sequentially oxidized in a 250 mL round-bottomed flask, a Dean-Stark trap is arranged, and the mixture is heated and refluxed for 6-12 hours at 112-120 ℃. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex.
In a preferred embodiment of the present invention, the mass ratio of the two substances of bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide and 3-bromothiophene-2-carboxylic acid is 1 (2-2.2).
In a preferred embodiment of the invention, the solvent toluene is added in an amount of 25 to 35 ml per millimole of tin bis [ tris (2-methyl-2-phenylpropyl) ] oxide.
The invention relates to an application of a tri (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex serving as a third aspect of the invention in preparation of anticancer drugs.
The applicant carries out in vitro anti-tumor activity confirmation research on the complex, and confirms that the complex has certain anti-tumor biological activity, namely the application of the complex in preparing anti-tumor drugs, in particular the application in preparing anti-human lung cancer drugs, human cervical cancer drugs and human gastric cancer drugs.
The tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex provided by the invention has good anticancer activity on human lung cancer cells, human cervical cancer cells, human gastric cancer cells and the like, and can be used as a raw material for preparing medicines for resisting lung cancer, cervical cancer and gastric cancer. Compared with the currently commonly used platinum anti-cancer drugs, the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex has the characteristics of high anti-cancer activity, low cost, simple preparation method and the like, and provides a new way for developing anti-cancer drugs.
Drawings
FIG. 1 is an IR spectrum of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex.
FIG. 2 is a diagram of a tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex 1 H NMR spectrum.
FIG. 3 is a diagram of a tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex 13 C NMR spectrum.
FIG. 4 is a diagram of a tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex 119 Sn NMR spectrum.
Detailed Description
The present invention is further illustrated in detail by the following examples, but it should be noted that the scope of the present invention is not limited by any of these examples.
Example 1:
preparation of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex:
in a 250 mL round bottom flask, bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide 1.0531 g (1 mmol), 3-bromothiophene-2-carboxylic acid 0.4143 g (2 mmol), solvent toluene 25 mL, and a Dean-Stark trap were added in order, and the mixture was heated to reflux at 112-120℃for reaction 6 h. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex. Yield: 81%, melting point: 88-89 ℃.
Elemental analysis (C) 35 H 41 BrO 3 SSn): theoretical value: c,58.03; h,5.71. Measurement value: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)。
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The crystallographic data thereof: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
example 2:
preparation of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex:
in a 250 mL round bottom flask, bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide 1.0536 g (1.0 mmol), 3-bromothiophene-2-carboxylic acid 0.4558 g (2.2 mmol), solvent toluene 25 mL, and a Dean-Stark trap were added in order, and the reaction was performed under reflux at 112-120℃with heating of 8 h. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex. Yield: 79%, melting point: 88-89 ℃.
Elemental analysis (C) 35 H 41 BrO 3 SSn): theoretical value: c,58.03; h,5.71. Measurement value: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)。
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The crystallographic data thereof: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
example 3:
preparation of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex:
in a 250 mL round bottom flask, bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide 1.0532 g (1.0 mmol), 3-bromothiophene-2-carboxylic acid 0.4560 g (2.2 mmol), solvent toluene 35 mL, and a Dean-Stark trap were added in order, and the reaction was performed under reflux at 112-120℃with heating of 8 h. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex. Yield: 80%, melting point: 88-89 ℃.
Elemental analysis (C) 35 H 41 BrO 3 SSn): theoretical value: c,58.03; h,5.71. Measurement value: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The crystallographic data thereof: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
example 4:
preparation of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex:
in a 250 mL round bottom flask, bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide 2.1063 g (2.0 mmol), 3-bromothiophene-2-carboxylic acid 0.8290 g (4.0 mmol), solvent toluene 50 mL, and a Dean-Stark trap were added in order, and the reaction was performed under reflux at 112-120℃with heating of 8 h. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex. Yield: 82%, melting point: 88-89 ℃.
Elemental analysis (C) 35 H 41 BrO 3 SSn): theoretical value: c,58.03; h,5.71. MeasuringAnd (3) setting: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)。
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The crystallographic data thereof: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
example 5:
preparation of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex:
in a 250 mL round bottom flask, bis [ tris (2-methyl-2-phenylpropyl) ] tin 2.1067 g (2.0 mmol), 3-bromothiophene-2-carboxylic acid 0.8288 g (4.0 mmol), solvent toluene 60 mL, and a Dean-Stark trap were added in order, and the reaction was heated at 112-120℃under reflux to give 12 h. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex. Yield: 80%, melting point: 88-89 ℃.
Elemental analysis (C) 35 H 41 BrO 3 SSn): theoretical value: c,58.03; h,5.71. Measurement value: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)。
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The crystallographic data thereof: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
example 6:
preparation of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex:
in a 250 mL round bottom flask, bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide 3.1592 g (3.0 mmol), 3-bromothiophene-2-carboxylic acid 1.2433 g (6.0 mmol), solvent toluene 75 mL, and a Dean-Stark trap were added in order, and the reaction was heated to reflux at 112-120℃to give 12 h. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex. Yield: 78%, melting point: 88-89 ℃.
Elemental analysis (C) 35 H 41 BrO 3 SSn): theoretical value: c,58.03; h,5.71. Measurement value: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)。
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The crystallographic data thereof: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
example 7:
preparation of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex:
in a 250 mL round bottom flask, bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide 3.1597 g (3.0 mmol), 3-bromothiophene-2-carboxylic acid 1.3670 g (6.6 mmol), solvent toluene 90 mL, and a Dean-Stark trap were added in order, and the reaction was performed under reflux at 112-120℃with heating of 6 h. After the reaction is finished, filtering while the solution is hot, removing the solvent from the filtrate by using a rotary evaporator to obtain a white solid, and recrystallizing the white solid by using ethanol to obtain the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex. Yield: 80%, melting point: 88-89 ℃.
Elemental analysis (C) 35 H 41 BrO 3 SSn): theoretical value: c,58.03; h,5.71. Measurement value: c,58.10; h,5.75.
IR(KBr, v/cm -1 ): 3049.46(w), 2960.73(s), 2920.23(m), 2862.36(m), 1658.78(s), 1598.99(w), 1498.69(m), 1440.83 (w), 1415.75(m), 1355.69(w), 1280.73(s), 1190.08(w), 1097.50(w), 1072.42(m),1029.99(w), 906.54(w), 881.47(m), 769.60(s), 698.23(s), 669.30(m), 615.29(w), 555.50(m), 455.20(w), 416.62(w)。
1 H NMR (CDCl 3 , 500 MHz) δ(ppm): 7.37 (d, J = 5 Hz, 1H), 7.30-7.26 (m ,6H), 7.22-7.19 (m, 3H), 7.11 (d, J = 8Hz, 6H), 7.06 (d, J = 5.5 Hz, 1H), 1.28 (s, 6H), 1.24 (s, 18H)。
13 CNMR(CDCl 3 , 125MHz) δ(ppm):164.07, 150.84, 132.68, 131.86, 129.78, 128.38, 125.85, 125.26, 114.62, 37.74, 37.70, 32.78 (t, J = 2.25 Hz)。
119 Sn NMR(CDCl 3 , 186 MHz), δ(ppm): 106.70。
The crystallographic data thereof: the crystals belong to triclinic system and space groupP -1a=0.95282(7) nm,b=1.14352(8) nm,c=1.61823(11) nm,α=100°,β=98°,γ=101°,Z=2,V=1.6792(8) nm 3Dc=1.433 Mg·m -3μ(MoKa)=2.041mm -1F(000)= 736,2.36°<θCrystal size < 25.01 °:0.23 x 0.21 x 0.26mm,R=0.0292,wR=0.0726。
test example:
the in vitro anticancer activity of the tri (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex is measured by an MTT (methyl thiazolyl tetrazolium) experimental method.
MTT assay:
based on the metabolic reduction of 3- (4, 5-dimethylazol-2-yl) -2,5-diArenyltetrazolium bromide. Succinate dehydrogenase in the mitochondria of living cells reduces exogenous MTT to water insoluble blue-violet crystalline Formazan (Formazan) and deposits in cells, whereas dead cells do not. Dimethyl sulfoxide (DMSO) can dissolve formazan in cells, and the optical density of characteristic wavelength can be measured by an enzyme-labeled instrument, so that the number of living cells can be indirectly reflected.
The inhibitory activity of the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex prepared in example 1 on human lung cancer cells (A549), human cervical cancer cells (Hela), and human gastric cancer cells (HGC-27) was determined by MTT assay.
Cell lines and culture system: a549, hela, and HGC-27 cell lines were obtained from American Tissue Culture Collection (ATCC). With 10% fetal bovine serum in RPMI1640 (GIBICO) medium at 5% (volume fraction) CO 2 In vitro culture was performed in a saturated humidity incubator at 37 ℃.
The testing process comprises the following steps: the test liquid medicine (0.0625 mu mol/L-0.5 mu mol/L) is added into each hole according to concentration gradient, and 3 parallel holes are arranged for each concentration. The experiments were divided into drug test groups (with different concentrations of test agent added), control groups (with only culture fluid and cells without test agent) and blank groups (with only culture fluid and no cells and test agent). The orifice plate after the drug addition is placed at 37 ℃ and 5 percent CO 2 Culturing in an incubator for 24 hours. The activity of the control drug was determined by the method of the test sample. In the well plate after 48 hours of incubation, MTT 20uL (5 g/L in PBS) was added to each well. After 4h at 37℃the supernatant was removed. 150uL DMSO was added to each well and the mixture was shaken for 10min to dissolve Formazan crystals. Finally, absorbance values of each well were measured at 570nm using a BioTek multifunctional microplate reader.
And (3) data processing: data processing uses the GraAr Pad Prism version5.0 programComplex IC 50 Fitting is performed through a nonlinear regression model with S-shaped dose response in the program.
The IC of the human lung cancer cell (A549) cell strain, the human cervical cancer cell (Hela) cell strain and the human gastric cancer cell (HGC-27) cell strain are determined by an MTT assay 50 Values, results are shown in table 1, conclusions are: as can be seen from the data in the table, the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex of the invention is used as an anticancer drug, has higher anticancer activity on human lung cancer, human breast cancer and human liver cancer, and can be used as a candidate complex of the anticancer drug. Has high anticancer activity on human lung cancer, human cervical cancer and human gastric cancer, and can be used as candidate complex of anticancer drugs.
Table 1 data for in vitro activity test of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex anticancer drugs.
Human lung cancer cell Human cervical cancer cell Human gastric cancer cell
Cell strain A549 Hela HGC-27
IC 50 μM 0.711 0.6601 0.2245
The test methods of the anti-cancer activity of the tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-carboxylate complex prepared in the other examples on human lung cancer cells (A549), human cervical cancer cells (Hela) and human gastric cancer cells (HGC-27) by using the MTT method are the same as those of the test examples, and the test results are basically the same as those of Table 1.

Claims (1)

1. The application of tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate in preparing anticancer drugs is characterized by being a complex with the following structural formula (I):
(I);
the cancer cell is human gastric cancer HGC-27.
CN201911364658.XA 2019-12-26 2019-12-26 Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof Active CN111269260B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911364658.XA CN111269260B (en) 2019-12-26 2019-12-26 Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911364658.XA CN111269260B (en) 2019-12-26 2019-12-26 Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN111269260A CN111269260A (en) 2020-06-12
CN111269260B true CN111269260B (en) 2023-09-22

Family

ID=70993702

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911364658.XA Active CN111269260B (en) 2019-12-26 2019-12-26 Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN111269260B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108997410A (en) * 2018-04-02 2018-12-14 衡阳师范学院 Three (adjacent bromobenzyl) tin -2- ester thiohenic acids of one kind and preparation method and application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108997410A (en) * 2018-04-02 2018-12-14 衡阳师范学院 Three (adjacent bromobenzyl) tin -2- ester thiohenic acids of one kind and preparation method and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis, Characterization, and In Vitro Cytotoxicity of Triorganotin 3,5-Di-tert-butyl-4-hydroxybenzoates;Wenchao Ding等;《Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry》;20120131;82-87 *

Also Published As

Publication number Publication date
CN111269260A (en) 2020-06-12

Similar Documents

Publication Publication Date Title
CN111057092B (en) Tris (2-methyl-2-phenylpropyl) tin 3-aminopyrazinate complex and preparation method and application thereof
CN111269260B (en) Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof
CN111138480B (en) Preparation method and application of tricyclohexyltin quinoline-4-formate complex
CN111138473B (en) Tris (2-methyl-2-phenylpropyl) tin 3-methyl-thiophene-2-formate and preparation method and application thereof
CN111138475B (en) Tris (2-methyl-2-phenylpropyl) tin 3-methylbenzofuran formate complex and preparation method and application thereof
CN111138476B (en) Tris (2-methyl-2-phenylpropyl) tin 2-chlorothiophene-5-formate complex and preparation method and application thereof
CN111116641B (en) Bis [ tri (2-methyl-2-phenyl) propyltin ] furan-2-formate complex and preparation method and application thereof
CN111057095B (en) Tricyclohexyltin 5-chloro-2-hydroxypyridine-3-formate complex and preparation method and application thereof
CN111138482B (en) Tris (2-methyl-2-phenylpropyl) tin 5-bromo-2-furoate complex and preparation method and application thereof
CN111116637B (en) Tris (2-methyl-2-phenylpropyl) stannquinoxaline-2-formate complex and preparation method and application thereof
CN111138474B (en) Tricyclohexyltin 2-bromothiophene-5-formate complex and preparation method and application thereof
CN111138483B (en) Tricyclohexyltin 2-chlorothiophene-5-formate complex and preparation method and application thereof
CN111138479B (en) Tricyclohexyltin 3-methylbenzofuran-2-formate complex and preparation method and application thereof
CN111138478B (en) Tricyclohexyltin quinoxaline-2-formate complex, and preparation method and application thereof
CN111057094B (en) Tris (2-methyl-2-phenylpropyl) tin benzothiophene-2-formate complex and preparation method and application thereof
CN111138484B (en) Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyltin ] fumarate complex
CN111057093B (en) Tricyclohexyltin benzothiophene-2-formate complex and preparation method and application thereof
CN111217851B (en) Preparation method and application of tricyclohexyltin indole-4-formate complex
CN111116638A (en) Tricyclohexyltin 3-methylthiophene-2-formate complex, and preparation method and application thereof
CN111138481B (en) Preparation method and application of tricyclohexyltin indole-3-formate complex
CN111116636B (en) Preparation method and application of tricyclohexyltin indole-6-formate complex
CN111138477B (en) Preparation method and application of tricyclohexyltin quinoline-6-formate complex
CN111138485B (en) Preparation method and application of tricyclohexyl tin cinnamate complex
CN111138487B (en) Preparation method and application of tricyclohexyltin 1-naphthoate complex
CN111057091B (en) Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyltin ] 5-amino isophthalic acid ester complex

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant